Cynata Therapeutics Ltd (ASX: CYP) is a clinical stage regenerative medicine company specializing in stem cell therapeutics that has a proprietary technology for manufacturing induced pluripotent stem cell (iPSC) derived mesenchymal stem cells (MSCs). Recently, I had the honor of interviewing Dr Ross Macdonald, CEO of Cynata Therapeutics. In this interview, we discuss Cynata’s technology platform, the company’s world first achievements, and its clinical trial underway for GvHD. We also explore the company’s strategic goals and the importance of its partnership with Fujifilm in Japan. [Read more…]
Since the discovery of induced pluripotent stem cells (iPS cells) in 2006, a great deal of basic research has been done to understand how to produce, manipulate, and utilize the cell type. iPS cells are revolutionizing regenerative medicine, because they represent a potential route for producing patient-specific stem cells for research applications or clinical use. iPS cells also show great promise for phamaco-toxicological screening, by allowing disease modeling and safety assessment of potential new drugs.
iPS Cells in Drug Discovery and Disease Modeling
iPS cells have the potential to transform drug discovery by providing physiologically relevant human cells for compound identification, target validation, compound screening, and tool discovery. They can be used to produce a wide variety of mature human cell types, allowing potential drug compounds to be screened in high-throughput systems using human cells.
Additionally, iPS cells allow for the creation of patient specific cell populations, facilitating in vitro drug testing that replicates the disease conditions of the patient population of interest. This approach facilitates early determination of whether a specific genetic population will respond well to a drug candidate, a process known as “personalized medicine.”
Currently, all but one of the clinical trials underway with iPS cells involve the creation and evaluation of iPS cell lines from specific patient population to determine whether the cell lines will be a good model for a disease of interest in a specific patient population. The only exception to this is Cynata’s clinical trial underway for GvHD in the UK that involves a MSC-derived iPS cell product. [Read more…]
With more than 200 different cell types in the human body, a key goal of Cellular Dynamics International (CDI), a Fujifilm company, is to continue to expand the portfolio of available human iPSC-derived tissues where possible and where there is a scientific need. For example, CDI’s first-generation GABAergic iCell Neurons are inhibitory cortical neurons that recapitulate many features of human neurons. The utility of this cell type was immediately demonstrated as an alternative model to primary animal-based neuronal preparations for assessing neurite outgrowth as well as developmental and general neuronal cytotoxicity. However, as they are a primarily inhibitory neuronal population, they provided limited utility for assessing networked neuronal electrical activity. [Read more…]
- iPSC technology is moving from a boutique phenomenon to industrialized cellular models.
- Increasing recognition by industry and regulatory bodies for detecting a variety of toxicities.
- Emerging utility for predicting cardio and neuro-related oncology adverse effects.
Founded in 2007 by Rudolf Jaenisch with backing from Arch Venture Partners, Fate Therapeutics’ corporate headquarters are in San Diego, California. It also has a subsidiary in Ottawa, Canada. Fate Therapeutics is an innovative biotechnology company developing novel stem cell modulators and biologic or small molecule compounds that guide cell fate. [Read more…]